Premium
P4‐378: A five‐way crossover study to evaluate the single‐dose effects of a novel 5‐HT6 receptor antagonist, PF‐07212377 (SAM‐760), on reversing psychomotor and cognitive deficits induced by scopolamine
Author(s) -
Bell Joanne M.,
Comery Thomas A.,
Lockwood Peter,
Huang Yifan,
Vandal Grace,
Maruff Paul,
Kupiec James
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.08.284
Subject(s) - donepezil , psychomotor learning , crossover study , psychology , placebo , cholinergic , antagonist , muscarinic antagonist , medicine , pharmacology , cognition , anesthesia , dementia , neuroscience , receptor , disease , alternative medicine , pathology
THE SINGLE-DOSE EFFECTS OFA NOVEL 5-HT6 RECEPTOR ANTAGONIST, PF-07212377 (SAM-760), ON REVERSING PSYCHOMOTOR AND COGNITIVE DEFICITS INDUCED BY SCOPOLAMINE Joanne M. Bell, Thomas A. Comery, Peter Lockwood, Yifan Huang, Grace Vandal, Paul Maruff, James Kupiec, Pfizer, Groton, Connecticut, United States; Pfizer Global Research and Development, Groton, Connecticut, United States; 3 Pfizer, Groton, Connecticut, United States; 4 Pfizer, Melbourne, Australia.